Last night, we reported adjusted earnings per diluted share for the second quarter of $3.40, with adjusted net income of $199 million and premium revenue of $6.6 billion.
The 88.4% medical care ratio demonstrates solid performance while managing through pandemic-related medical cost challenges that increased the ratio by 110 basis points.
Our six month year-to-date performance, highlighted by an 87.6% MCR, a 7% adjusted G&A ratio and a 3.4% after-tax margin were all squarely in line with our year-to-date expectations.